KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$358.24
−3.56%Margins
Gross margin
93.3%
EBITDA margin
49.6%
EBIT margin
44.9%
Net margin
54.8%
FCF margin
58.5%
17.8%
Return on equity
16.1%
Return on assets
14.5%
Return on invested capital
0.30x
Asset turnover
$272.3M
Cash from operations
$29
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026